1. Detection of cardiac amyloidosis with 18 F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy.
- Author
-
Kircher M, Ihne S, Brumberg J, Morbach C, Knop S, Kortüm KM, Störk S, Buck AK, Reiter T, Bauer WR, and Lapa C
- Subjects
- Adult, Aged, Amyloidosis blood, Aniline Compounds, Biomarkers blood, Female, Heart Failure blood, Heart Failure diagnostic imaging, Humans, Male, Middle Aged, Stilbenes, Treatment Outcome, Young Adult, Amyloidosis diagnostic imaging, Echocardiography, Heart diagnostic imaging, Magnetic Resonance Imaging, Positron Emission Tomography Computed Tomography, Radionuclide Imaging
- Abstract
Purpose: Cardiac amyloidosis (CA) is a rare cause of heart failure with frequently delayed diagnosis, because specific early signs or symptoms are missing. Recently, direct amyloid imaging using positron emission tomography/computed tomography (PET/CT) has emerged. The aim of this study was to examine the performance of
18 F-florbetaben-PET/CT in detection of CA, and compare it to echocardiography (echo), cardiac MRI (CMR) and scintigraphy. Additionally, the use of18 F-florbetaben-PET/CT for quantification of amyloid burden and monitoring of treatment response was assessed., Methods: Twenty-two patients with proven (n = 5) or clinical suspicion (n = 17) of CA underwent18 F-florbetaben-PET/CT for diagnostic work-up. Qualitative and quantitative assessment including calculation of myocardial tracer retention (MTR) was performed, and compared to echo (n = 20), CMR (n = 16), scintigraphy (n = 16) and serologic biomarkers (NT-proBNP, cTnT, free light chains). In four patients, follow-up PET/CT was available (after treatment initiation, n = 3; surveillance, n = 1)., Results: PET demonstrated myocardial18 F-florbetaben retention consistent with CA in 14/22 patients. Suspicion of CA was subsequently dropped in all eight PET-negative patients. Amyloid subtypes showed characteristic retention patterns (AL > AA > ATTR; all p < 0.005). MTR correlated with morphologic and functional parameters, as measured by CMR and echo (all r| > 0.47|, all p < 0.05), but not with cardiac biomarkers. Changes in MTR from baseline to follow-up corresponded well to treatment response, as assessed by cardiac biomarkers and performance status., Conclusions: Imaging of cardiac amyloidosis (CA) with18 F-florbetaben-PET/CT is feasible and might be useful in differentiating CA subtypes.- Published
- 2019
- Full Text
- View/download PDF